Logotype for Niagen Bioscience Inc

Niagen Bioscience (NAGE) Q4 2020 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Niagen Bioscience Inc

Q4 2020 earnings summary

19 Nov, 2026

Executive summary

  • Q4 2020 net sales rose 18% YoY to $15.4M; Tru Niagen sales rose 21% YoY to $12.3M, with continued sequential growth.

  • FY 2020 net sales increased 28% to $59.3M; adjusted EBITDA excluding legal expense improved to a $1.0M loss from an $8.8M loss in 2019.

  • Ended 2020 with $16.7M in cash and raised $25M through a common-stock investment in February 2021.

Financial highlights

  • Q4 net loss was $6.1M, or $0.10/share, versus a $8.9M loss, or $0.15/share, in Q4 2019; operating loss narrowed to $6.1M from $8.9M.

  • Q4 net sales were $15.4M, up 18% YoY and 9% QoQ; FY sales were $59.3M, up 28% YoY.

  • FY 2020 net loss was $19.9M versus $32.1M in 2019; cash used in operations was $10.6M versus $20.4M.

Outlook and guidance

  • FY 2021 outlook calls for continued steady revenue growth, supported by global e-commerce and existing and new strategic partnerships.

  • Gross margin expected to be slightly above 60%; selling and marketing and R&D expected to remain roughly flat as a share of sales.

  • Adjusted EBITDA excluding legal expense expected to improve modestly as higher sales and gross margins are largely offset by investments to scale the business.

  • Planned investments include brand awareness, R&D pipeline and new NAD precursor development, key personnel, and infrastructure.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Niagen Bioscience